SeaSpine Holdings Corporation provided earnings guidance for the fourth quarter and full-year 2020. Preliminary and unaudited revenue for fourth quarter 2020 is expected to be in the range of $46.2 to $46.6 million, reflecting approximately 6% to 7% growth compared to the prior year period. Fourth quarter 2020 U.S. Spinal Implants revenue is expected to reflect growth within the 7% to 8% range and U.S. Orthobiologics revenue is expected to reflect growth within the 6% to 7% range. International revenue is expected to decrease 3% to approximately $4.3 million. In the fourth quarter of 2020, total year-over-year revenue growth was tracking to exceed the 8% year-over-year revenue growth achieved in the third quarter of 2020. Preliminary and unaudited full-year 2020 revenue is expected to be in the range of $154.1 to $154.5 million, reflecting a decline of approximately 3% compared to full-year 2019.